The same research group developed another self-assembling lipid–polymer hybrid nanoparticle delivery system consisting of therapeutic p53 mRNA into p53 null hepatocellular carcinoma (HCC) and NSCLC cells. This evidence concerns the gene TP53 and hepatocellular carcinoma.